Plandai Biotechnology Inc (OTCMKTS:PLPL) producer of the Phytofare® reported that Azochem Laboratories placed the second purchase order for Phytofare® Catechin Complex. Callum Cottrell-Duffield, the VP of Sales & Marketing said that as part of exclusive three year deal with USN to supply its manufactures with their patented green tea extract, the product will be available on shelves worldwide.

Azochem is one of the contract manufacturers for USN and is based in South Africa. Cottrell-Duffield added that they take seriously all contractual requirements to supply to USN contractors quickly and efficiently and manage all of the USN logistic components linked with sales.

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Retains William M. Merino

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) a Pharma firm formulating innovative therapeutic products reported that they have retained William (Bill) Merino as company’s senior clinical and regulatory advisor.

Dr. Merino has years of experience working with the global and U.S. pharmaceutical approval process, quality control, and quality assurance, having served more than thirty years in senior regulatory affairs role at firms like Alcon Pharmaceuticals, Riker Laboratories, G. D. Searle & Co. and others. He joins Ritter as the company focuses on advancing its lead candidate, RP-G28 into advanced Phase IIb/3 trials.

Carbylan Therapeutics Inc (NASDAQ:CBYL) Reports 2Q2015 Results

Carbylan Therapeutics Inc (NASDAQ:CBYL) reported the financial results for 2Q ending June 30, 2015. The net loss in 2Q2015 came at $9.0 million compared to $2.6 million in the second quarter of 2014.

David Renzi, the CEO and President said that during the second quarter, they continued to move forward with Phase III clinical trial for Hydros-TA targeting osteoarthritis pain of the knee. Additionally, the company completed the enrollment in COR1.1 trial, which marks as the first of the two key clinical studies needed for NDA for Hydros-TA.

IN last trading session, the stock price of Plandai gained more than 2% to close the trading session at $0.143.